Associated Papers
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors.
Sheng J et al.
Npj Precision Oncology, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P et al.
British Journal of Cancer, 2024
Liquid Biopsy Profiling with Multiple Tests in Patients with Metastatic Breast Cancer.
Higa N et al.
Journal of Molecular Pathology, 2024
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.
Xu Y et al.
Npj Precision Oncology, 2023
Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
Boyarskikh UA et al.
Bulletin of Experimental Biology and Medicine, 2023
Progressive metastatic infantile fibrosarcoma with multiple acquired mutations.
Furtado LV et al.
Cold Spring Harbor Molecular Case Studies, 2023
Kinase inhibitors in thyroid cancers.
Sukrithan V et al.
Endocrine Oncology (bristol, England), 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Kinase Fusion-Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics.
Chu YH et al.
Endocrine Pathology, 2022
JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J et al.
Molecules (basel, Switzerland), 2022
Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.
Wang ZZ et al.
Briefings in Bioinformatics, 2022
Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
Mei LC et al.
European Journal of Medicinal Chemistry, 2022
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z et al.
Journal of Medicinal Chemistry, 2022
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT et al.
Frontiers in Oncology, 2022
Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
Zhuo LS et al.
Journal of Medicinal Chemistry, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Keddy C et al.
Cold Spring Harbor Molecular Case Studies, 2021
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco E et al.
Cancer Discovery, 2021
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R et al.
Communications Biology, 2020
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A et al.
Current Oncology Reports, 2020
Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
Jin W
Cancers, 2020
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Okamura R et al.
Jco Precision Oncology, 2018